Ariad Pharmaceuticals Inc. (NASDAQ:ARIA)’s share price rose 1.7% on Friday . The company traded as high as $7.26 and last traded at $7.15, with a volume of 1,380,974 shares traded. The stock had previously closed at $7.03.

A number of equities research analysts have issued reports on ARIA shares. JMP Securities restated a “buy” rating on shares of Ariad Pharmaceuticals in a research note on Monday, June 6th. Cowen and Company reiterated a “buy” rating and set a $10.00 price objective on shares of Ariad Pharmaceuticals in a research note on Monday, June 6th. William Blair reiterated a “buy” rating and set a $10.00 price objective on shares of Ariad Pharmaceuticals in a research note on Tuesday, May 24th. Jefferies Group reiterated a “buy” rating and set a $13.00 price objective on shares of Ariad Pharmaceuticals in a research note on Tuesday, May 24th. Finally, Zacks Investment Research upgraded Ariad Pharmaceuticals from a “hold” rating to a “buy” rating and set a $8.50 price objective for the company in a research note on Tuesday, July 5th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and five have issued a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus price target of $9.06.

The firm’s 50 day moving average is $7.83 and its 200-day moving average is $6.62. The company’s market cap is $1.36 billion.

Ariad Pharmaceuticals (NASDAQ:ARIA) last announced its quarterly earnings data on Tuesday, May 10th. The pharmaceutical company reported ($0.23) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.27) by $0.04. The company had revenue of $35.60 million for the quarter, compared to analysts’ expectations of $43.06 million. The business’s quarterly revenue was up 48.3% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.28) EPS. Equities research analysts forecast that Ariad Pharmaceuticals Inc. will post ($0.60) earnings per share for the current fiscal year.

In related news, Director Massimo Radaelli sold 108,569 shares of Ariad Pharmaceuticals stock in a transaction that occurred on Tuesday, June 14th. The stock was sold at an average price of $8.25, for a total transaction of $895,694.25. Following the transaction, the director now owns 128,088 shares in the company, valued at $1,056,726. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Paris Panayiotopoulos acquired 26,990 shares of Ariad Pharmaceuticals stock in a transaction that occurred on Thursday, May 12th. The shares were bought at an average price of $7.41 per share, for a total transaction of $199,995.90. Following the transaction, the chief executive officer now owns 61,099 shares of the company’s stock, valued at approximately $452,743.59. The disclosure for this purchase can be found here.

Other institutional investors recently made changes to their positions in the company. Rhumbline Advisers increased its position in shares of Ariad Pharmaceuticals by 7.8% in the fourth quarter. Rhumbline Advisers now owns 174,193 shares of the pharmaceutical company’s stock worth $1,089,000 after buying an additional 12,560 shares during the last quarter. ProShare Advisors LLC increased its position in shares of Ariad Pharmaceuticals by 10.3% in the fourth quarter. ProShare Advisors LLC now owns 176,600 shares of the pharmaceutical company’s stock worth $1,104,000 after buying an additional 16,552 shares during the last quarter. New York State Common Retirement Fund increased its position in shares of Ariad Pharmaceuticals by 18.0% in the fourth quarter. New York State Common Retirement Fund now owns 193,180 shares of the pharmaceutical company’s stock worth $1,207,000 after buying an additional 29,480 shares during the last quarter. California State Teachers Retirement System increased its position in shares of Ariad Pharmaceuticals by 1.6% in the fourth quarter. California State Teachers Retirement System now owns 310,276 shares of the pharmaceutical company’s stock worth $1,939,000 after buying an additional 5,000 shares during the last quarter. Finally, Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp increased its position in shares of Ariad Pharmaceuticals by 13.1% in the fourth quarter. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp now owns 1,418,866 shares of the pharmaceutical company’s stock worth $8,868,000 after buying an additional 164,580 shares during the last quarter.

ARIAD Pharmaceuticals, Inc (ARIAD) is an oncology company. The Company is focused on transforming the lives of cancer patients with medicines. The Company’s product pipeline includes Iclusig (ponatinib), brigatinib, AP32788 and ridaforolimus. The Company’s Iclusig is a tyrosine kinase inhibitor (TKI) that is approved in the United States, the European Union, Australia, Switzerland, Israel and Canada for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.